Avtor/Urednik		Žegura, Branka; Keber, Irena; Šebeštjen, Miran; Koenig, Wolfgang
Naslov		Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis
Tip		članek
Vir		Atherosclerosis
Vol. in št.		Letnik 158
Leto izdaje		2003
Obseg		str. 123-9
Jezik		eng
Abstrakt		Estrogen replacement therapy (ERT) has been found to be associated with increased cardiovascular risk in the first year after initiation of ERT. We compared the effects of oral and transdermal estradiol (E2) replacement therapy on markers of inflammation, coagulation and fibrinolysis in a randomized double-blind trial. Forty-three healthy women were randomized 6 weeks after surgically-induced menopause to receive treatment with either oral or transdermal-E2-over a period of 28-weeks. At baseline and after 28 weeks, levels of serum lipids and lipoproteins, and markers of coagulation, fibrinolysis and inflammation were determined. Among fibrinolytic parameters, oral E2 shortened euglobulin clot lysis time (P < 0.05) and reduced tissue type plasminogen activator antigen (P = 0.01) and plasminogen activator inhibitor activity (P < 0.05). Among coagulation parameters, both routes of E2 replacement decreased fibrinogen levels (P = 0.002 for oral and P = 0.007 for transdermal E2). Oral E2 resulted in an increase in C-reactive protein (CRP) from 2.15 (0.71-4.05) to 3.41 (1.12-5.92) mg/l (P = 0.04), while transdermal E2 showed no effect. Levels of serum amyloid A (SAA), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) did not change significantly after oral and transdermal E2. Oral E2 significantly improved the lipid profile, while transdermal E2 had a less pronounced effect. Both oral and transdermal E2 significantly reduced fasting glucose. Oral E2 was associated with a pro-inflammatory response, but at the same time improved fibrinolytic capacity, showed no pro-coagulatory effects, and acted beneficially on lipids and lipoproteins. There was no influence of transdermal E2 on markers of coagulation activation, fibrinolysis and inflammation, but it decreased fibrinogen levels significantly. Further studies are needed to explore the clinical relevance of these observations.
Deskriptorji		ESTROGEN REPLACEMENT THERAPY HYSTERECTOMY ESTRADIOL LIPOPROTEINS BLOOD COAGULATION TESTS DOUBLE-BLIND METHOD RANDOMIZED CONTROLLED TRIALS FIBRINOLYSIS CLOT RETRACTION PLASMINOGEN ACTIVATORS PLASMINOGEN INACTIVATORS FIBRINOGEN C-REACTIVE PROTEIN AMYLOID INTERLEUKIN-6 TUMOR NECROSIS FACTOR